OOIR: Observatory of International Research

Papers

(The median citation count of ESMO Open is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	283
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	252
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	177
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	170
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	154
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	146
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	134
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	126
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	120
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	116
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	112
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	104
Table of Contents	103
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	99
Table of Contents	98
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	98
Table of Contents	94
ESMO	92
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	84
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	83
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	82
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	77
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	74
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	73
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	72

143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	63
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	62
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	61
Editorial Board	60
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	60
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	58
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	57
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	56
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	55
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	54
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	53
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	53
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	52
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	51
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	51
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	50
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	50
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	49
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	49
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	49
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	48
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	48
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	47
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	47
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	47
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	46
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	44
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	43
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	42
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	42
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer	41
Editorial Board	41
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies	41
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	41
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	40
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	40
Editorial Board	40
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	40
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	39
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	39
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	39
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	38
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	37
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	37
Editorial Board	37
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	37
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	36
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	36
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	36
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	36

36P Next-generation sequencing in liquid biopsy for advanced NSCLC: Indian tertiary cancer centre experience	35
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	35
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?	35
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	35
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India	35
58P Peripheral T cell phenotypes as predictors of progression and treatment response in mCRC: A prospective immunoprofiling study	35
8P Unveiling functional reprogramming in pancreatic cancer: An integrative transcriptomic and explainable machine learning approach	35
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis	34
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study	34
43eP Is age a risk factor for locally advanced cervical cancer persistence?	33
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	33
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	33
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy	32
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	31
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	31
71P Relapse rate in patients avoiding adjuvant chemotherapy based on Oncotype DX score: Real-world data from three UK centres	30
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	30
90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)	30
Implementing SERENA6 in the clinic in the UAE: critical thinking of a community oncologist	30
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	30
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	30
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation	29
238P Comparing the benefit-risk profiles of emerging treatments in early breast cancer (eBC) using the ESMO MCBS and the ASCO value framework	29
307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial	29
225P The impact of predictive genomic testing in Ireland: Financial and resource implications for healthcare institutions and patients	29
148P AI driven adjuvant therapy: Predicting pCR from radiological data in patients receiving incomplete NACT for LABC	29
393P Treatment outcomes and toxicity of palbociclib in metastatic hormone receptor (HR)-positive HER2 -ve breast cancer patients: Real-life palbociclib outcome in Omani patients	29
420P Physicians’ knowledge, practice and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: Results of the ABC6 and ABC7 survey	29
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	28
438P Antidepressants/anxiolytics and breast cancer treatment: The case of drug-drug interactions	28
72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICC	28
222P Hemoglobin A1c screening for patients with early breast cancer treated with adjuvant endocrine therapy	28
334P The nationwide Advanced Breast Cancer - Patient Care Initiative (ABC-PCI): A medical oncologist-led survey on quality of life in Chinese patients with metastatic triple-negative breast cancer	28
357P BRCA genetic testing implementation and the impact of BRCA pathogenic variant status on clinical outcomes in HER2-negative metastatic and recurrent breast cancer in Japan	28
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN	27
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	27
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	27
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	27
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial	27
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	26
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	26
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	26
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	26
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	26
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	26
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities	25
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	25
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	25
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	24
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	24
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	24
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	24
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	24
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	24
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer	24
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	24
Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: developme	24
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	24
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	24
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	24
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	23
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)	23
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	23
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	23
E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study	23
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	23
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA	23
Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study	23
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	22
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	22
283P Incidence of male breast cancer in genetically high-risk patients	22
439P The bio-psycho-social predictors of mental health among women with breast cancer	22
23P Anti-tumor activity of novel Globo-H targeting CAR T cells in cholangiocarcinoma model	22
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	22
481P Trends in mortality due to malignant and benign breast neoplasms in the United States from 2018 to 2023: A CDC wonder analysis	22
273P Clinicopathological features and outcomes in patients with BRCA-associated HR+/HER2- breast cancers eligible for adjuvant CDK4/6 and PARP inhibitors	22
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	22
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	22
Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-	22
301MO Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer: BCT1703 DIAmOND	22

487P Health care provider’s adherence to clinical practice guidelines in diagnosing and staging breast cancer: An observational study	21
53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer	21
246P Four years of Oncotype DX test in clinical practice: the experience of the breast unit of University Hospital of Parma	21
229P Risk of recurrence and overall survival in Stage II and III ER+/HER2- early breast cancer: A population-based registry study in Sweden	21
398P Evaluation of trastuzumab deruxtecan for metastatic HER2+ breast cancer: A meta-analysis	21
220P Efficacy and saftey of neoadjuvant trastuzumab, pyrotinib and chemotherapy in HER2-positive breast cancer: A real-world study	21
430P Analysis of quality of life in a group of very long-term early stage breast cancer survivors	21
24P The role of radiotherapy for intermediate-risk in early-stage cervical cancer post-radical hysterectomy: A meta-analysis	20
134P Gene alterations in Mongolian breast cancer patients	20
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial	20
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial	20
178P Comparative study between wise pattern and non-vertical scar reduction mammoplasty	20
136P Vascular endothelial growth factor A (VEGF-A) expressions in invasive breast cancer and its association with lymph node metastasis and histopathologic features	20
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis	20
37eP Local control with chemoradiotherapy in patients with metastatic cervical cancer	20
120P Genetic associations of plasma proteins and breast cancer: Potential therapeutic drug candidates	20
56P Neoadjuvant treatment with sequential letrozole and exemestane in postmenopausal patients with HR-positive, HER-2 negative breast cancer: Clinical and biomarker outcomes from the NEOLETEXE trial	20
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer	20
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer	19
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer:	19
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	19
189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial	19
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer	19
44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial	19
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)	19
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	19
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	19
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study	19
Editorial Board	18
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	18
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	18
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	18
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	18
154P Alternative splicing in non-small cell lung cancer evolution	18
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	18
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	18
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	18
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	18
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	18
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy	18
224P Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibito	18
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	18
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	18
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	18
57P Multi-matrix untargeted metabolomics profiling reveals potential non-invasive prognostic and predictive biomarkers in metastatic colorectal cancer: The CRC-Tsen study	17
MAP 2025 Officers and Organisation	17
70eP Decoding ambiguity of variants of uncertain significance (VUS) of non-small cell lung carcinoma (NSCLC) using a comprehensive NGS panel: Landmark study from an Indian cohort	17
268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation	17
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical O	17
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	17
45P Phenotypic diversity of lynch syndrome and the role of NGS in its molecular characterization	17
17eP Fitzpatrick-guided AI system for ABCD-based dermoscopic analysis and melanoma risk stratification	17
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phas	17
74P Evaluation of the clinical significance of rare epidermal growth factor receptor exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small cell lung cancer: A five-yea	17
Table of Contents	17
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer	17
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	17
127O Response to TIL therapy depends on a tumor-intrinsic IL-2 signaling axis that drives expansion of CD25+ tumor-reactive T cells	17
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses	17
65eP Real-world impact of pembrolizumab plus lenvatinib in metastatic uveal melanoma: A retrospective multicenter study	17
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	17
124P Melittin inhibits the growth of hepatocellular carcinoma Huh7 cells by downregulating LARS2 and ZNF19	17
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	17
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study	17
142P Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis	16
PP064 MicroRNA 200c-3p targeting CDH1 gene polymorphism towards risk susceptibility of prostate cancer in North Indian population	16
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	16
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	16
153P BRAF variants and therapy outcomes in melanoma	16
29P First-line of camrelizumab, apatinib mesylate and chemotherapy for advanced high-grade neuroendocrine tumors (NETS): A single center, single arm, exploratory study	16
45P Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence	16
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	16
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	16
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	16
PP065 In silico genetic polymorphisms analysis of GSTP1 and their effect on platinum compound and antituberculosis drugs co-medication in lung cancer patients with tuberculosis comorbidity	16
79P Real-world comparative analysis of liposomal doxorubicin and paclitaxel in first-line treatment of Kaposi sarcoma: A retrospective study in Brazil	16
18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate	16
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	16
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	16
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	16
114P Effects of chemotherapy on TREG lymphocytes in early breast cancer	16
252P Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project	15
80P Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs	15
117P Merkel cell carcinoma: Epidemiological pattern in the United States, a SEER based study	15
96P Age-adjusted trends and survival analysis of alveolar soft part sarcoma	15
18P PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response	15
139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis	15
11P Conization before radical hysterectomy in early cervical cancer: A Korean multi-center study	15
14P Unravelling the immune landscape of non-epithelial ovarian cancer	15
OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC	15
90P Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients? A real-life study	15
108P Establishing a multi-modal tissue preparation and imaging workflow to study heterogeneity in neuroblastoma tumors	15
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece	15
83P Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin	15
PP108 Is it possible to avoid seroma after mastectomy and axillary lymph node dissection using microporous polysaccharide hemispheres (AristaTM)?	15